Chinese Investment in Kazakhstan’s Pharmaceutical Manufacturing
On August 26, 2026, a delegation from Yangtze River Pharmaceutical Group (China) visited the laboratories and pilot pharmaceutical production facilities of JSC Research and Production Center Phytochemistry in Karaganda, Kazakhstan. The delegation was headed by Chen Zehao, Special Representative of the China–Kazakhstan Working Committee on the Digital Development of Artificial Intelligence in Traditional Chinese Medicine, and included the following representatives: Yang Hui, Head of the Overseas Operations Department of Yangtze River Pharmaceutical Group; Tong Jinghui, Head of the Central Asia Region at China International Construction; Song Yuliang, Representative of China International Construction for Central Asia; Liu Xiaoming, Executive Chairman of the China–Kazakhstan Association for Cultural and Economic Cooperation; Liu Junfang, General Manager for Overseas Markets at Huai’an Tiancheng Sanitary Products Co., Ltd., Deputy Head of the China People’s Livelihood Research Group.
During the visit, the parties discussed opportunities for cooperation and the expansion of pharmaceutical manufacturing capacities to supply pharmaceutical substances derived from medicinal plants grown in Kazakhstan to China.
 |
 |
 |
 |
The proposed Kazakhstan–China joint project, to be implemented at JSC Research and Production Center Phytochemistry, aims to expand pharmaceutical production and diversify the range of original medicines developed in Kazakhstan from locally sourced medicinal plant materials. The project envisages attracting Chinese investment and introducing advanced technologies for processing medicinal plant raw materials.
The implementation of this project will create new opportunities for cooperation with Chinese pharmaceutical companies, facilitate the potential registration of original Kazakhstani medicines in China, and open up prospects for the use of innovative herbal medicines developed in Kazakhstan within traditional Chinese medicine.
 |
 |
 |
 |
Key factors supporting this initiative include the local availability of medicinal plant resources and the need to reduce dependence on imports. Achieving these objectives requires the introduction of innovative technologies for the extraction and processing of medicinal plant materials, which will help reduce production costs and improve product quality.
The combination of advanced technologies provided by the Chinese partners and locally sourced medicinal plant materials for the production of original herbal medicines is expected to enhance their competitiveness in both domestic and international markets, while improving their availability and helping to address existing shortages.
As a result of the visit, a Protocol of Intent on Joint Cooperation was signed between JSC Research and Production Center Phytochemistry (Karaganda, Republic of Kazakhstan) and Yangtze River Pharmaceutical Group (People’s Republic of China).
 |
 |
 |
 |